APLUS Coalition Urges Congressional Support for Rare Disease Patients!

Please reach out to your elected officials to stand with the bleeding disorders and other chronic disease communities by urging them to join the Congressional Plasma Caucus!

In May of this year, HFA, NHF and the eleven national patient organizations that make up the American Plasma Users (APLUS) Coalition, applauded the creation of the Congressional Plasma Caucus. The American Plasma Users (APLUS) Coalition represents the over 125,000 Americans living with chronic disorders, including bleeding disorders, that depend upon plasma-derived therapies to lead healthy, productive lives.

This bipartisan Caucus aims to:

  • Educate lawmakers about rare disease, blood and plasma supply and safety initiatives.
  • Emphasize the vital role of plasma in treating various life-threatening and chronic conditions.
  • Bring together stakeholders from America’s plasma donors, suppliers, and patients to ensure the safety and availability of plasma and plasma-derived therapies in the United States.
  • Highlight the patient voice in  issues affecting patients who depend on plasma-derived treatment, including those with bleeding disorders.
  • Enhance the influence of patient stories and perspectives, patient advocacy organizations, and experts in blood and plasma safety in policymaking.

While the Caucus has made strides in membership over the last two months, the leaders of the Caucus have emphasized the need for more membership. Members of Congress want to hear from the bleeding disorders community as to why this is so important.

American Plasma Users Coalition Urges Congressional Support for Rare Disease Patients

Please enter a complete address to continue.

Dear [recipient position will go here] [recipient name will go here],

Sincerely,
[your name will go here]
[your location will go here]
[your email address will go here]

This campaign is hosted by Hemophilia Federation of America. We will protect your privacy, and keep you informed about this campaign and others.